XML 46 R35.htm IDEA: XBRL DOCUMENT v3.25.3
SCHEDULE OF NUMERATOR AND DENOMINATOR OF BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Accounting Policies [Abstract]        
Net Income (loss) from continuing operations $ 834,493 $ (180,488) $ 714,186 $ (2,872,286)
Net Loss from discontinued operations (31,246,601) (2,702,564) (36,672,075) (5,339,011)
Less: Net loss from continuing operations attributable to noncontrolling interests (955) (1,740) (5,197) (3,224)
Less: Net loss from discontinued operations attributable to noncontrolling interests (23,544) (82,107)
Net loss attributable to Sanara MedTech shareholders $ (30,411,153) $ (2,857,768) $ (35,952,692) $ (8,125,966)
Weighted average shares, basic 8,646,668 8,517,381 8,610,538 8,468,394
Dilutive effect of stock options 31,013 31,013
Dilutive effect of unvested shares 263,053 266,014
Weighted average shares, diluted 8,940,734 8,517,381 8,907,565 8,468,394
Net income (loss) per share, basic:        
Continuing operations $ 0.10 $ (0.02) $ 0.08 $ (0.34)
Discontinued operations (3.62) (0.32) (4.26) (0.62)
Net income (loss) per share of common stock, basic (3.52) (0.34) (4.18) (0.96)
Net income (loss) per share, diluted:        
Continuing operations 0.09 (0.02) 0.08 (0.34)
Discontinued operations (3.49) (0.32) (4.12) (0.62)
Net income (loss) per share of common stock, diluted $ (3.40) $ (0.34) $ (4.04) $ (0.96)